Sort by
Refine Your Search
-
Listed
-
Category
-
Employer
- University of Nottingham
- UCL;
- UNIVERSITY OF SOUTHAMPTON
- KINGS COLLEGE LONDON
- Nature Careers
- UNIVERSITY OF MELBOURNE
- University of Birmingham
- University of Nottingham;
- Cardiff University
- EMBL-EBI - European Bioinformatics Institute
- King's College London
- Plymouth University
- SINGAPORE INSTITUTE OF TECHNOLOGY (SIT)
- The University of Edinburgh;
- University of Plymouth;
- University of Southampton;
- University of Sussex;
- jobs.ac.uk
- 8 more »
- « less
-
Field
-
generating DNA cytosine modification dysfunction in IPF, and potential targets for therapeutic interference in IPF development. Applicants must be highly motivated and self-driven, with a PhD in bioinformatics
-
31/10/2028 in the first instance. Appointment at Grade 7 is dependent upon having been awarded a PhD; if this is not the case, initial appointment will be at Grade 6B with payment at Grade 7 being
-
with a PhD in molecular biology, adept at computational and functional genomics, and eager to lead innovative research in a collaborative setting. You may also: Have a proven track record in
-
an active member of our Postdoctoral Fellow community About You: You should have, or will soon have, a PhD in computational biology, molecular biology, genetics, or biochemistry. You will have flexibility
-
, neuroimaging, neurophysiology, proteomics, transcriptomics, epigenomics, metabolomics, bioinformatics, cell models and animal models. First in man and Phase 2, 3 and 4 clinical trials are also strongly supported
-
. Essential Criteria Qualifications and Education Postgraduate degree at PhD level in a related subject area or relevant industrial experience Knowledge, Skills and Experience An established expertise and
-
March 2026 (with some flexibility). Applicants should have a PhD in Microbiology, ideally in the area of antimicrobial resistance, awarded or submitted at the time of taking up the position. In
-
, neuroimaging, neurophysiology, proteomics, transcriptomics, epigenomics, metabolomics, bioinformatics, cell models and animal models. First in man and Phase 2, 3 and 4 clinical trials are also strongly supported